Paul Hastings Wins Four-Year ICC Arbitration for Mitsubishi Tanabe

Paul Hastings obtained a complete victory for Mitsubishi Tanabe at the International Court of Arbitration of the International Chamber of Commerce (ICC) against Novartis Pharma AG. The tribunal denied all of Novartis’ claims in a dispute covering past and future royalties worth billions of dollars, including $940 million in already-paid royalties. The tribunal also awarded our client more than $22 million in fees and costs.

This licensing dispute concerned Novartis’ royalty payments for the blockbuster drug product Gilenya. While Japanese law governed the applicable contract, the dispute involved critical systemic global issues regarding the IP and competition laws of the United States, the European Union and Japan. The tribunal comprised three of the world’s leading ICC arbitrators seated in London.

Global IP practice co-chair Eric Dittmann led the team, which also included partners Chad Peterman, Young Park, Joshua Bennett, of counsel Sachiko Taniguchi and associates Rebecca Hilgar, Ryan Meuth and Matthew Morantz.

More information can be found here: https://globalarbitrationreview.com/article/japanese-pharma-group-declares-win-in-billion-dollar-royalties-dispute